Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status

Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status

Objectives To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast. Methods Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and...

Full description

Bibliographic Details
Main Authors: Steven R. Feldman, Jingchuan Zhang, Diane J. Martinez, Lorena Lopez-Gonzalez, Elizabeth Hoit Marchlewicz, George Shrady, Alan M. Mendelsohn, Yang Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2021-02-01
Series:Journal of Dermatological Treatment
Subjects:
psoriasis
metabolic conditions
biologic therapy
apremilast
Online Access:http://dx.doi.org/10.1080/09546634.2019.1698699

Similar Items

Similar Items